Eric Nicolai

USPTO Granted Patents = 10 (Patent Applications = 5)

EPO Patents = 10 (Patent Applications = 11)

Average Co-Inventor Count = 5.8

ph-index = 2

Forward Citations = 62(Granted Patents)

Location History:

Antony, FR (2011)
Paris, FR (2012 - 2018)

Company Filing History:

Years Active: 2011-2018

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10077237 - Oxindole derivatives, preparation thereof and therapeutic use in the treatment of AMPK-related diseases (2018-09-18),

2. 9120812 - Pyrimidooxazocine derivatives as mTOR-inhibitors (2015-09-01),

3. 8546391 - Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof (2013-10-01),

4. 8536173 - Tetrahydroquinoxaline urea derivatives as modulators of 11-B-hydroxysteroid dehydrogenase type I (2013-09-17),

5. 8530657 - Substituted adamantanes and their therapeutic application (2013-09-10),

6. 8530477 - Tropane urea derivatives, preparation thereof and therapeutic application thereof as modulators of the activity of 11betaHSD1 (2013-09-10),

7. 8530473 - Tetrahydroquinoxaline urea derivatives as modulators of 11β-hydroxysteroid dehydrogenase type 1 (2013-09-10),

8. 8211892 - Tetrahydroquinoxaline urea derivatives (2012-07-03),

9. 7947834 - Substituted quinoxalines, their preparation and their therapeutical use as 11βHSD1 modulators (2011-05-24),

10. 7897773 - Urea derivatives of tropane, their preparation and their therapeutic application (2011-03-01),

Title: Eric Nicolai: Innovator in Pharmaceutical Chemistry

Introduction

Eric Nicolai is a prominent inventor based in Paris, France. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target various diseases. With a total of 10 patents to his name, Nicolai's work has the potential to impact the treatment of conditions such as diabetes and obesity.

Latest Patents

Among his latest patents, Nicolai has developed oxindole derivatives, which are compounds that modulate the activity of AMP-activated protein kinase (AMPK). This invention focuses on the preparation and therapeutic use of these compounds in treating AMPK-related diseases. Another notable patent involves pyrimidooxazocine derivatives, which serve as mTOR-inhibitors. This invention includes a process for preparing these bicyclic heterocyclic derivatives and outlines their therapeutic applications.

Career Highlights

Throughout his career, Nicolai has worked with leading pharmaceutical companies, including Sanofi and Sanofi-Aventis. His experience in these organizations has allowed him to refine his expertise in drug development and innovation.

Collaborations

Nicolai has collaborated with several notable professionals in his field, including Olivier Venier and Claudie Namane. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Eric Nicolai's innovative work in pharmaceutical chemistry exemplifies the impact of dedicated inventors in the medical field. His contributions continue to pave the way for new treatments and therapies that address critical health issues.

This text is generated by artificial intelligence and may not be accurate.